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However, the physiological role of CTRP6 remains poorly understood. Here we demonstrate that
the globular domain of CTRP6 mediates the phosphorylation and activation of the 50-AMP-activated
protein kinase (AMPK) in skeletal muscle cells. In parallel with the activation of AMPK, CTRP6
induces the phosphorylation of acetyl coenzyme A carboxylase (ACC) and fatty acid oxidation in
myocytes. Thus, CTRP6 plays a role in fatty acid metabolism via the AMPK-ACC pathway.
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C1qTNF-related protein-6 (CTRP6) is a 240-amino acid protein
that consists of a signal peptide, a short variable region, a colla-
gen-like region, and a C-terminal globular domain. It belongs to a
family of proteins characterized by a common TNF alpha-like glob-
ular domain. Although CTRP family proteins are structurally re-
lated, they are involved in diverse processes including
metabolism, inﬂammation host defense, apoptosis, cell differentia-
tion, autoimmunity, hibernation, and organogenesis [1,2]. CTRP1
inhibits collagen-induced platelet aggregation by speciﬁcally
blocking binding of the von Willebrand factor to collagen [3] and
also stimulates aldosterone production [4]. CTRP2 increases glyco-
gen accumulation and fatty acid oxidation by the activation of
AMP-activated protein kinase [5]. CTRP3/CORS26/Carducin is in-
volved in regulating both chondrogenesis and cartilage develop-
ment, and also has anti-inﬂammatory properties [6,7]. Mutation
of CTRP5 leads to insufﬁcient levels of secreted CTRP5, causing
late-onset retinal macular degeneration [8,9]. CTRP9 reduces ser-
um glucose and forms a heterodimer with adiponectin [10]. How-
ever, the function of CTRP6 remains poorly investigated.
AMP-activated protein kinase (AMPK) is a key regulatory en-
zyme that controls cellular and whole-body energy homeostasis
[11]. AMPK is mainly activated by an increase in the AMP to ATPchemical Societies. Published by E
.ratio, and it participates in cellular energy control by turning on
ATP-generating catabolic pathways, such as glucose transport
and fatty acid oxidation [11,12]. When activated by hypoxia or
muscle contraction, AMPK induces phosphorylation of acetyl-CoA
carboxylase (ACC), thereby activating fatty acid oxidation [13,14].
Recently, a new, highly conserved family of adiponectin paralogs,
designated as CTRP isoforms 1–10, was identiﬁed by searching
mouse and human ESTs and genome databases [5].
Among these, CTRP2 is similar to adiponectin and rapidly in-
duces phosphorylation of AMPK, ACC, and mitogen-activated pro-
tein kinase (MAPK) in C2C12 myotubes, which increases
glycogen accumulation and fatty acid oxidation [15]. We previ-
ously showed that CTRP5 activates AMPK and is increased in mito-
chondrial DNA (mtDNA)-depleted myocytes [10]. A recent study
showed that the expression level of CTRP6 is signiﬁcantly in-
creased in 12-week ob/ob mice relative to lean controls [5]. These
ﬁndings compelled us to speculate that CTRP6 may be involved
in fat metabolism. In this study, we present evidence that CTRP6
can stimulate fatty acid oxidation via the activation of AMP-acti-
vated protein kinase (AMPK).
2. Materials and methods
2.1. Reagents
Polyclonal antibodies directed against AMPKa, phospho-AMP-
Ka (Thr172), phospho-ACC (Ser79), Akt, phospho-Akt (Ser473),lsevier B.V. All rights reserved.
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naling Technology. The anti-actin antibody was purchased from
Sigma. Horseradish peroxidase (HRP)-conjugated anti-mouse IgG
and anti-rabbit IgG were obtained from Santa Cruz. AICAR was ac-
quired from Toronto Research Chemicals. Insulin (porcine crystal-
line) and Adenine 9-b-D-arabinofuranoside (AraA) were acquired
from Sigma.
2.2. Cell culture
C2C12 myocytes (ATCC CCL-1) were grown in Dulbecco’s mod-
iﬁed Eagle medium (DMEM) supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS) and the appropriate antibiotics.
To induce differentiation, the cells were grown to 100% conﬂuence
in maintenance medium and then switched to differentiation med-
ium (DMEM supplemented with 2% horse serum).
2.3. Generation of recombinant CTRP6 proteins
To produce GST-fusion protein corresponding to the globular
domain of human CTRP-6, the fragment of CTRP-6 cDNA encoding
amino acids 145-273 was generated by PCR and cloned into the
BamHI and XhoI sites of pGEX 4T-1. The recombinant protein was
expressed in Escherichia coli BL21, harvested, and puriﬁed using
Glutathione Sepharose™ fast ﬂow, in accordance with the manu-
facturer’s instructions (Pharmacia). To remove endotoxin, the puri-
ﬁed proteins were loaded in Detoxi-Gel (Pierce) before storage at
70 C.
2.4. Phosphoprotein analysis
C2C12 myotubes were serum-starved for 2 h and treated with
AICAR (2 mM), insulin (100 nM) or recombinant proteins. The cells
were immediately washed three times with ice-cold phosphate-
buffered saline (PBS) and lysed in cold lysis buffer [20 mM Tris–
HCl (pH 7.4), 200 mM NaCl, 1% Triton X-100, 1 mM phenylmethyl-
sulphonyl ﬂuoride, 5 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7,
1 mM pyrophosphatase, 1 lM pepstatin A, 1 lM leupeptin, and
1 lM aprotinin] for 30 min with vortex mixing. Equal amounts
(30 lg) of cell lysates were resolved by 6% or 10% SDS–PAGE, and
separated proteins were electrophoretically transferred to a nitro-
cellulose membrane (Bio-Rad). The membranes were incubated in
blocking solution consisting of 5% skim milk in TTBS [10 mM Tris–
HCl (pH 8.0), 150 mM NaCl, and 0.1% Tween 20] for 1 h at room
temperature, and then immunoblotted with the indicated phos-
pho-speciﬁc antibody. After overnight incubation, the membranes
were extensively washed with TTBS and incubated with HRP-con-
jugated anti-rabbit or anti-mouse IgG. Proteins were visualized
using an enhanced chemiluminescent substrate kit (Amersham
Bioscience). Immunoblot intensities were quantitated by densi-
tometry using an analytical scanning system (Molecular Dynamics
Inc., Sunnyvale, CA).
2.5. Fatty acid oxidation
Fatty acid oxidation assays were performed as previously de-
scribed [16] with slight modiﬁcations. Brieﬂy, C2C12 myotubes
were serum-starved for 2 h and incubated with preincubation buf-
fer (DMEMmedium containing 4 mM glutamine, 25 mMHEPES, 1%
fatty acid-free BSA, and 0.25 mM palmitate) for 1 h in 12-well
plates. Following addition of 14C-palmitate (1 lCi/ml), the cells
were incubated for 90 min at 37 C in the presence of globular
CTRP6 (10 lg/ml) or GST (10 lg/ml) proteins. Each well was cov-
ered with a piece of Whatman paper and ﬁxed using tape and incu-
bated for 90 min at 37 C. After incubation, 200 ll of 3 M NaOH
solution was applied to the edge of the paper and saturated the en-tire sheet by capillary action, and then 0.1 ml of 70% perchloric acid
(Sigma) was injected into the wells with a syringe. The ﬁlter paper
was removed from each well after collection of CO2 for 1 h at room
temperature. The amount of 14C-radioactivity was determined by a
liquid scintillation counter (Perkin–Elmer). For some experiments,
the cells were pretreated with AraA (2 mM) for 1 h prior to addi-
tion of gCTRP6.
2.6. Statistical analysis
Statistical signiﬁcance was assessed using t-test and ANOVA. A
P value of <0.05 was considered to be statistically signiﬁcant.3. Results and discussion
3.1. The globular domain of CTRP6 stimulates the phosphorylation of
AMPK in a dose- and time-dependent manner
Several CTRP isoforms, such as CTRP2, CTRP5, and CTRP9, in-
duce phosphorylation of AMP-activated protein kinase (AMPK) in
C2C12 myotubes, which thereby regulates glucose and fat metab-
olism [5,15,17]. The CTRP6 transcript is signiﬁcantly upregulated in
12-week ob/ob mice relative to age-matched controls, suggesting
that CTRP6 is potentially involved in fat metabolism [10]. To inves-
tigate the effect of CTRP6 on the activation of AMPK, which plays a
central role in fat metabolism, we generated full-length and the
globular domain of human CTRP6 as GST-fusion proteins. Although
we made multiple efforts, the full-length CTRP6 could be produced
only at very low concentrations. In a recent study, the size of serum
CTRP6 on immunoblots corresponded to its globular head rather
than the full-length protein [16]. We therefore used the globular
domain of CTRP6 (gCTRP6) for our experiments. Treatment with
gCTRP6 rapidly stimulated the phosphorylation of AMPK in
C2C12 myotubes (Fig. 1A). The effect peaked at 45 min (3.5-fold in-
crease over the untreated control; P < 0.001) (Fig. 1B). In addition,
the effects of gCTRP6 on AMPK phosphorylation occurred in a dose-
dependent manner (Fig. 1C). After treatment with 10 lg/ml of
gCTRP6, AMPK phosphorylation increased by approximately four-
fold, which is comparable to the effects of stimulation by AICAR,
a cell-permeable activator of AMPK (P = 0.004) (Fig. 1D). GST alone
had no effect on activation of AMPK. These results indicate that
CTRP6 could be involved in fat metabolism via the activation of
AMPK.
3.2. The AMPK-ACC pathway is a target of CTRP6
The activation of AMPK stimulates the phosphorylation and
inhibition of acetyl-CoA carboxylase (ACC), with a consequent
reduction of malonyl-CoA synthesis that stimulates fatty acid oxi-
dation [15]. Therefore, we investigated whether gCTRP6 induces
the phosphorylation of ACC in C2C12 myotubes. In parallel with
activation of AMPK, treatment of C2C12 myotubes with gCTRP6 in-
duced the phosphorylation of ACC (Fig. 2A). After treatment with
10 lg/ml of gCTRP6, ACC phosphorylation increased by approxi-
mately 2.9-fold, compared to GST-treated control (P = 0.001)
(Fig. 2B). This result suggests that gCTRP6 stimulates the deactiva-
tion of ACC through the activation of AMPK. In skeletal muscle,
adiponectin activates p38 MAPK in addition to AMPK, which in-
creases glucose uptake and fatty acid oxidation [18]. In a recent
study, CTRP9 activates AMPK and Akt in C2C12 myotubes and low-
ered serum glucose levels in obese mice [19]. However, treatment
of C2C12 myotubes with the globular domain of CTRP6 did not in-
duce the phosphorylation of p38 MAPK or the insulin signaling
intermediate, Akt (Fig. 2). Thus, CTRP6 is a potent and selective
activator of the AMPK-ACC pathway and is independent of the
Fig. 1. Phosphorylation of AMPK by the globular domain of human CTRP6 in C2C12 myotubes. (A) C2C12 myotubes were treated with 10 lg/ml of GST-fused globular domain
of human CTRP6 (gCTRP6) for the indicated times. The cells were lysed as described in Section 2. Equal amounts (30 lg) of cell lysates were subjected to SDS-PAGE and
immunoblotted with antibodies directed against AMPK, phospho-AMPK (Thr172, pAMPK), and actin. A representative result from three independent experiments is shown.
(B) Immunoblot intensities for pAMPK/AMPKwere quantitated by densitometry and expressed in arbitrary units. The intensity of the untreated control was set to one. Results
are expressed as the mean ± S.D. of three independent experiments. t-test; *P < 0.05 compared with untreated control. (C) C2C12 myotubes were serum-starved for 2 h and
treated with AICAR (2 mM), GST (10 lg/ml), or one of three different concentrations (1, 3, and 10 lg/ml) of gCTRP6 for 45 min. Immunoblot analysis was performed using
antibodies directed against AMPK, phospho-AMPK, and actin. A representative result from three independent experiments is shown. (D) Immunoblot intensities for pAMPK/
AMPK were quantitated by densitometry and expressed in arbitrary units. The intensity of the untreated control was set to one. Results are expressed as the mean ± S.D. of
three independent experiments. t-test; *P < 0.05 compared with untreated control.
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on the activation of AMPK-ACC pathway, we examined the effect
of AraA, an inhibitor of AMPK, on CTRP6-mediated signaling. Pre-
treatment with AraA signiﬁcantly inhibited gCTRP6-stimulated
phosphorylation of AMPK and ACC (Fig. 3), indicating that ACC is
a downstream signaling molecule of CTRP6-stimulated phosphory-
lation of AMPK.
3.3. gCTRP6 induces fatty acid oxidation
In muscle, activated AMPK phosphorylates and inhibits ACC,
leading to a decrease in fatty acid synthesis and a concomitant in-
crease in the b-oxidation of fatty acids [20]. We investigated
whether gCTRP6 stimulates fatty acid oxidation. Treatment with
the globular domain of CTRP6 caused a 1.5-fold increase in 14C-pal-
mitate oxidation in C2C12 myotubes compared to untreated con-
trol (P < 0.002), whereas GST alone had no effect (Fig. 4A). In
addition, gCTRP6-mediated palmitate oxidation was signiﬁcantly
inhibited by pretreatment of araA (P = 0.004) (Fig. 4B). Since CTRP6
phosphorylates ACC via the activation of AMPK, the induction of
fatty acid oxidation by CTRP6 is mainly due to activation of the
AMPK-ACC pathway.
CTRP family proteins all consist of an N-terminal signal peptide,
a variable region, a collagen (Gly-X-Y) repeat and a C-terminal C1q-
like globular domain [10]. The last exon of CTRP6 encodes the en-
tire C-terminal globular domain, which is a functional domain that
may interact with the protein’s ligand or a receptor. A fragment
corresponding to the globular domain of adiponectin (globular
adiponectin) has been shown to be present in serum [5] and to ex-
hibit potent metabolic effects [20–23]. Furthermore, globular
adiponectin has a high afﬁnity for binding to AdipoR1, which is
predominantly expressed in skeletal muscle [24]. Since the size
of CTRP6 in serum corresponds to its globular domain rather than
the full-length protein [25], CTRP6 may undergo proteolytic pro-
cessing. In this study, we found that the globular domain of CTRP6mediates fatty acid oxidation via activation of the AMPK-ACC path-
way. Among CTRP isoforms involved in glucose and fat metabo-
lism, CTRP2 and CTRP9 are predominantly expressed in adipose
tissues [26]. However, CTRP5 and CTRP6 are widely expressed in
many tissues [15], suggesting that they may act in physiological
or pathological conditions via a different expression mechanism.
Indeed, we recently found that CTRP5 is upregulated in mtDNA-de-
pleted myocytes and activates AMPK [15]. In a recent study, the
serum level of CTRP6 was signiﬁcantly increased in adiponectin-
null mice [15]. Consistent with this ﬁnding, CTRP6 transcripts were
increased in 12-week-old ob/ob mice, which showed decreased
adiponectin expression relative to their lean controls [16]. Consid-
ering that adiponectin activates AMPK and fatty acid oxidation in
human skeletal muscles [15], these ﬁndings raise the possibility
that, under certain conditions, CTRP6 plays a role in compensating
for the loss of adiponectin. In addition, CTRP1 is the closest homo-
log of CTRP6 among CTRP family proteins and can form a heterodi-
mer with CTRP6 [15,27], which suggests that CTRP1 may also be
involved in CTRP6 functions, such as fatty acid oxidation. It re-
mains to be determined whether the two proteins are functionally
linked.
Although our results provide evidence that CTRP6-stimulated
phosphorylation of AMPK activates fatty acid oxidation, activation
of AMPK also can induce an increase in glucose uptake via GLUT4
translocation [5]. It has been reported that globular adiponectin
and CTRP5 induces glucose uptake via the translocation of GLUT4
[15,26]. Our preliminary data show that the globular domain of
CTRP6 can also stimulate the translocation of GLUT4 in L6 GLUT4-
myc cells (unpublished data). Thus, it remains to be determined
whether CTRP6 induces glucose uptake via the translocation of
GLUT4. In summary, the results of the present study show that
CTRP6 mediates fatty acid oxidation via the AMPK-ACC pathway.
Although the expression pattern and function of CTRP6 in meta-
bolic diseases is still unclear, the identiﬁcation of CTRP6 as a func-
tional protein that mediates the oxidation of fatty acids in muscle
Fig. 2. gCTRP6 induces the phosphorylation of ACC and is independent of Akt and
p38 MAPK pathways. (A) C2C12 myotubes were serum-starved for 2 h and treated
with insulin (100 nM), AICAR (2 mM), GST (10 lg/ml), or three different concen-
trations (1, 3, and 10 lg/ml) of gCTRP6 for 45 min. The cells were lysed as described
in Section 2. Equal amounts (30 lg) of cell lysates were subjected to SDS–PAGE and
immunoblotted with antibodies directed against AMPK, phospho-AMPK (Thr172,
pAMPK), ACC, phospho-ACC (Ser79, pACC), Akt, phospho-Akt (Ser473, pAkt), p38
MAPK (p38), phospho-p38 MAPK (pp38), and actin. A representative result from
three independent experiments is shown. (B) Immunoblot intensities for pACC/ACC
were quantitated by densitometry and expressed in arbitrary units. The intensity
for GST-treated control was set to one. Results are expressed as the means ± S.D. of
three independent experiments. t-test; *P < 0.05 compared with GST control.
Fig. 3. AraA, an inhibitor of AMPK, inhibits the phosphorylation of AMPK and ACC
by globular CTRP6. C2C12 myotubes were serum-starved for 2 h and treated with
AICAR (2 mM), GST (10 lg/ml), or gCTRP6 (10 lg/ml), with or without 1-h
pretreatment of AraA (2 mM). The cells were lysed as described in Section 2. Equal
amounts (30 lg) of cell lysates were subjected to SDS–PAGE and immunoblotted
with antibodies directed against AMPK, phospho-AMPK, ACC, phospho-ACC, and
actin. A representative result from three independent experiments is shown.
Fig. 4. Effect of gCTRP6 on fatty acid oxidation in C2C12 myotubes. (A) C2C12
myotubes were starved of serum for 2 h and washed twice with HEPES-buffered
saline solution. The cells were treated with GST (10 lg/ml) or GST-gCTRP6 (10 lg/
ml) for 45 min. The fatty acid oxidation rate was measured as 14CO2 generation
from 14C-palmitate. The trapped 14CO2 and 14C-labeled acid soluble products were
determined by liquid scintillation counting and expressed as a relative ratio, where
the radioactivity of untreated control cells was set to one. Results are expressed as
the mean ± S.D. of three independent experiments. AVOVA: *P < 0.05. (B) C2C12
myotubes were treated with GST-gCTRP6 (10 lg/ml), with or without 1-h
pretreatment of AraA (2 mM). The fatty acid oxidation was measured as 14CO2
generation from 14C-palmitate. The trapped 14CO2 and 14C-labeled acid soluble
products were determined by liquid scintillation counting and expressed as a
relative ratio, where the radioactivity of GST-treated cells was set to one. Results are
expressed as the mean ± S.D. of three independent experiments. t-test: *P < 0.05.
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